Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect
Launched by ASAN MEDICAL CENTER · Mar 26, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help doctors choose the right size device to close a hole in the heart called an atrial septal defect (ASD). The researchers want to see if using a special 3D imaging technique called three-dimensional transesophageal echocardiography can accurately predict the best device size needed for successful closure before the procedure. This method allows doctors to better understand the size and shape of the defect, which is important for a successful treatment.
To be eligible for this study, participants must be at least 18 years old and have a medical need for ASD closure. However, those with multiple defects or other serious heart conditions that require open heart surgery are not suitable for this trial. If you join the study, you can expect to undergo imaging tests and have your device size calculated using a specific formula. This research aims to improve the way heart defects are treated, helping patients have better outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 year-old
- • Susceptible indication for atrial septal defect closure
- • Potential candidate for device closure
- Exclusion Criteria:
- • Poor candidate for device closure: multiple ASDs, ect
- • Other heart disease requiring open heart surgery
About Asan Medical Center
Asan Medical Center, located in Seoul, South Korea, is a leading healthcare institution renowned for its commitment to advanced medical research and patient care. With a focus on innovative clinical trials, the center aims to enhance healthcare outcomes through rigorous scientific investigation and collaboration. Asan Medical Center is equipped with state-of-the-art facilities and a multidisciplinary team of experts dedicated to exploring new therapeutic approaches across various medical fields. Its robust infrastructure supports a wide range of clinical studies, contributing significantly to the global medical community's understanding of diseases and treatment efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Jong-Min Song, MD PhD
Principal Investigator
Asan Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials